ARTICLE | Emerging Company Profile
Impact founder Hood launches Endeavor with $62M to address pulmonary diseases
Emerging Company Profile: Endeavor is starting with a hedgehog inhibitor from Eli Lilly in IPF
January 8, 2021 2:16 AM UTC
Endeavor launched Thursday with $62 million from a series A financing round led by Omega Funds and Longitude Capital to treat pulmonary diseases, starting with a hedgehog pathway inhibitor in-licensed from Eli Lilly.
John Hood, co-founder, chairman and CEO Endeavor BioMedicines, previously founded Impact Biomedicines Inc., which Celgene Corp. acquired in 2018 for $1.1 billion up front. That deal gave Celgene myelofibrosis drug Inrebic fedratinib, an oral JAK-2 inhibitor. ...